RRPV Solicitation Summary: Agnostic Diagnostics

Description

{"description":" This solicitation summary is to notify all potential offerors of a Request for Project Proposals (RPP) issued through the Rapid Response Partnership Vehicle (RRPV) Consortium on behalf of the Biomedical Advanced Research and Development Authority (BARDA) entitiled "Agnostic Diagnostics". The full RPP and information on joining the consortium can be accessed through the RRPV website www.rrpv.org. \n\n The purpose of this RPP is to support the advanced development, clinical evaluation, and FDA clearance of mNGS-based diagnostic assays for viral and bacterial pathogen detection. BARDA seeks highly flexible, rapidly adaptable systems capable of identifying all known viral and bacterial pathogens within a given specimen (e.g., respiratory sample) and reconfiguring-through database or software updates—to detect emerging pathogens during public health emergencies. BARDA requires the use of existing mNGS-based sequencing platforms or mNGS platforms that are already in development. Both laboratory and point-of-care mNGS solutions are sought. \n"} Solicitation Number: RRPV-RPP-26-09-AgDx Type: Special Notice Base Type: Special Notice NAICS: 541714 Classification Code: AN42 Response Deadline: 2025-11-20T13:00:00-05:00 Office Address: WASHINGTON, DC POC: Rebecca Harmon, rebecca.harmon@ati.org {"description":" This solicitation summary is to notify all potential offerors of a Request for Project Proposals (RPP) issued through the Rapid Response Partnership Vehicle (RRPV) Consortium on behalf of the Biomedical Advanced Research and Development Authority (BARDA) entitiled "Agnostic Diagnostics". The full RPP and information on joining the consortium can be accessed through the RRPV website www.rrpv.org. \n\n The purpose of this RPP is to support the advanced development, clinical evaluation, and FDA clearance of mNGS-based diagnostic assays for viral and bacterial pathogen detection. BARDA seeks highly flexible, rapidly adaptable systems capable of identifying all known viral and bacterial pathogens within a given specimen (e.g., respiratory sample) and reconfiguring-through database or software updates—to detect emerging pathogens during public health emergencies. BARDA requires the use of existing mNGS-based sequencing platforms or mNGS platforms that are already in development. Both laboratory and point-of-care mNGS solutions are sought. \n"}